company background image
IMMX logo

Immix Biopharma NasdaqCM:IMMX Stock Report

Last Price

US$2.08

Market Cap

US$54.9m

7D

2.0%

1Y

0.5%

Updated

22 Jul, 2024

Data

Company Financials +

Immix Biopharma, Inc.

NasdaqCM:IMMX Stock Report

Market Cap: US$54.9m

IMMX Stock Overview

A clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia.

IMMX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Immix Biopharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Immix Biopharma
Historical stock prices
Current Share PriceUS$2.08
52 Week HighUS$7.75
52 Week LowUS$1.55
Beta0.17
11 Month Change1.96%
3 Month Change-9.57%
1 Year Change0.48%
33 Year Changen/a
5 Year Changen/a
Change since IPO-43.32%

Recent News & Updates

Recent updates

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Nov 28
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?

Jul 12
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?

We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

Mar 29
We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans

Sep 13
Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely

May 21
We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely

Shareholder Returns

IMMXUS BiotechsUS Market
7D2.0%0.2%-2.1%
1Y0.5%12.5%19.0%

Return vs Industry: IMMX underperformed the US Biotechs industry which returned 12.5% over the past year.

Return vs Market: IMMX underperformed the US Market which returned 19% over the past year.

Price Volatility

Is IMMX's price volatile compared to industry and market?
IMMX volatility
IMMX Average Weekly Movement13.7%
Biotechs Industry Average Movement10.6%
Market Average Movement5.9%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: IMMX's share price has been volatile over the past 3 months.

Volatility Over Time: IMMX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201216Ilya Rachmanwww.immixbio.com

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd.

Immix Biopharma, Inc. Fundamentals Summary

How do Immix Biopharma's earnings and revenue compare to its market cap?
IMMX fundamental statistics
Market capUS$54.94m
Earnings (TTM)-US$18.21m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMMX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$18.21m
Earnings-US$18.21m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.69
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did IMMX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.